Therefore, despite limited reports on the therapeutic efficacy of IL-13Rα2 in sarcomas, inhibition of IL-13Rα2 might enhance the efficacy of doxorubicin and potentially other chemotherapeutic agents, thereby improving outcomes for osteosarcoma patients with high IL-13Rα2 expression. This evidence concerns the gene IL13RA2 and sarcoma.